Cancer Investigation · 2009 · 29 citations · 28 references
MedicineOncologyPharmacologyCell ProliferationChemotherapyTumor ProgressionAngiogenesisAngiogenesis In CancerCancer ProgressionGrowth Factor SignalingOvarian Cancer PharmacotherapyTumor PromotionCancer Cell Proliferation InhibitionMalignant AscitesTumor Growth DynamicsTumor Growth RateVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor Signaling
Vascular endothelial growth factor (VEGF) is the key molecule mediating tumor growth and malignant ascites formation. We recently reported that, in an end stage OVCAR-3 xenograft model, albendazole (ABZ) suppresses ascites formation, but not tumor growth. Hence, in the present study, we assessed the effect of ABZ on in vitro OVCAR-3 cell proliferation plus in vivo tumor growth, however, initiating ABZ treatment at mid stage (3 weeks post cell inoculation) rather than end stage disease. Here, ABZ treatment led to potent inhibition of cell proliferation, VEGF suppression, complete inhibition of ascites formation and most strikingly arrest of tumor growth.
28
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
VEGF-Trap: A VEGF blocker with potent antitumor effects
Jocelyn Holash, Sam Davis, Susan D. Croll et al. · Proceedings of the National Academy of Sciences · 2002 · 1.7K citations
Medicine, Oncology, Pharmacology +17
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Dai Fukumura, Ramnik J. Xavier, Takeyuki Sugiura et al. · Cell · 1998 · 979 citations · Full text